Company news
Twist Bioscience Corporation (NASDAQ:TWST) news
Twist Bioscience Corporation news releases on 6ix. Latest, Jan 19, 2021: Twist Bioscience Signs Two Biopharma Technology Agreements to Enable Novel…
Press releases — page 5
Twist Bioscience Signs Two Biopharma Technology Agreements to Enable Novel Therapeutics Discovery
January 18, 2021
Twist Bioscience Begins Shipping of Synthetic RNA Controls for UK Variant Strain of SARS-CoV-2
January 13, 2021
Twist Bioscience Supplies Centers for Disease Control and Prevention with Custom SARS-CoV-2 Synthetic RNA Controls
January 6, 2021
Twist Bioscience to Offer Synthetic RNA Control for UK Variant Strain of SARS-CoV-2
December 22, 2020
Twist Bioscience to Expand Commercial Capabilities with Factory of the Future
December 21, 2020
Twist Bioscience Expands Gene Product Line with Launch of Clonal-Ready Gene Fragments
December 9, 2020
Twist Bioscience Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
December 6, 2020
Twist Bioscience Announces Pricing of a $300 Million Upsized Public Offering of Common Stock
December 1, 2020
Twist Bioscience Reports Fourth Quarter and Full Year Fiscal 2020 Financial Results
November 22, 2020
Twist Bioscience Continues Support for Next Generation of Synthetic Biologists Through Work with iGEM Competition
November 15, 2020
Twist Bioscience to Report Fiscal 2020 Fourth Quarter and Full Year Financial Results on Monday, November 23, 2020
November 1, 2020
Twist Bioscience Collaborates With Beyond Earth to Launch Artwork Stored in DNA Into Space
October 26, 2020
Twist Bioscience to Host Virtual Biopharma Analyst & Investor Event on October 23, 2020
October 12, 2020
Twist Bioscience Announces Potent SARS-CoV-2 Neutralizing Data from COVID-19 Therapeutic Antibody Program
September 1, 2020
Twist Bioscience Synthetic DNA Stores New Netflix Original Series ‘BIOHACKERS’
August 19, 2020
Twist Bioscience Reports Third Quarter Fiscal 2020 Financial Results
August 5, 2020
Twist Bioscience to Report Fiscal 2020 Third Quarter Financial Results on Thursday, August 6, 2020
July 29, 2020
Twist Bioscience Launches Two SARS-CoV-2 Antibody Panels to Expedite Research for COVID-19
July 27, 2020
Twist Bioscience Appoints Erin Smith Senior Vice President, Government Affairs and Public Policy
July 22, 2020
Twist Bioscience Launches Synthetic Controls for Respiratory Viruses
July 21, 2020
Twist Bioscience Partners with Invetx to Deliver Best-in-Class Antibody Therapeutics for Dogs and Cats
July 15, 2020
Twist Bioscience Adds Respiratory Virus Panel to Infectious Disease Product Line
June 29, 2020
Twist Bioscience Expands Offering of Synthetic SARS-CoV-2 RNA Controls
June 10, 2020
Twist Bioscience Announces Pricing of a $100 Million Public Offering of Common Stock
June 2, 2020
Twist Bioscience Reports Second Quarter Fiscal 2020 Financial Results
May 6, 2020
Twist Bioscience Identifies Competitive Antibodies for SARS-CoV-2
May 5, 2020
Twist Bioscience Expands Flexibility of Clonal Genes for Pharmaceutical, Biotechnology and Industrial Chemical Research
April 19, 2020
Twist Bioscience Partners with Vanderbilt University Medical Center to Supply Critical Products and Identify Antibody Therapeutics for COVID-19
March 25, 2020
Twist Announces Availability of Next-Generation Sequencing Target Enrichment Panel for SARS-CoV-2/COVID-19 Research
March 15, 2020
Twist Bioscience Announces Availability of Synthetic SARS-CoV-2 RNA Controls
March 11, 2020
Twist Bioscience and Miroculus Agree to Collaborate on Next-Generation Sequencing Target Enrichment and Library Preparation Tools for Clinical Research
February 24, 2020
Twist Bioscience Announces Pricing of Upsized $130.0 Million Public Offering of Common Stock
February 18, 2020
Twist Bioscience Now ISO 27001:2013 Certified for Information Security Management System
February 11, 2020
Twist Bioscience Reports First Quarter Fiscal 2020 Financial Results
February 5, 2020
CORRECTING and REPLACING Twist Bioscience Announces Completion of $50 Million Offering Priced At-The-Market
January 30, 2020
Twist Bioscience Announces Completion of $50 Million Registered Direct Offering Priced At-The-Market
January 26, 2020
Twist Bioscience to Report Fiscal 2020 First Quarter Financial Results on Thursday, February 6, 2020
January 22, 2020
Twist Bioscience Announces Strategic Collaboration With Schrödinger for Drug Discovery
January 14, 2020
Twist Bioscience Promotes Patrick Weiss to Chief Operating Officer Setting Stage for Future Growth
January 12, 2020
Twist Bioscience Reports Fourth Quarter and Full Year Fiscal 2019 Financial Results
December 10, 2019
Twist Bioscience Promotes Patrick J. Finn, Ph.D., to Chief Commercial Officer
November 19, 2019
Twist Bioscience Appoints Seasoned Life Sciences Industry Executive Nicolas M. Barthelemy to Board of Directors
October 24, 2019